徐诺药业 Revenue and Competitors

Dover, DE USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • 徐诺药业's estimated annual revenue is currently $3M per year.(i)
  • 徐诺药业's estimated revenue per employee is $201,000

Employee Data

  • 徐诺药业 has 15 Employees.(i)
  • 徐诺药业 grew their employee count by 0% last year.

徐诺药业's People

NameTitleEmail/Phone
1
Chairman, CEO & PresidentReveal Email/Phone
2
Chief Development OfficerReveal Email/Phone
3
Chief Development Officer and EVP QualityReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$44.4M22131%N/AN/A
#2
$10.3M51-27%N/AN/A
#3
$83.2M4146%N/AN/A
#4
$59.9M298-9%N/AN/A
#5
$9.4M4742%N/AN/A
#6
$136.3M678-8%N/AN/A
#7
$29.9M14913%N/AN/A
#8
$0.7M70%N/AN/A
#9
$3M1550%N/AN/A
#10
$9.6M487%N/AN/A
Add Company

What Is 徐诺药业?

Xynomic Pharmaceuticals, Inc. is a US incorporated biopharmaceutical company founded by US-China industry veterans and successful entrepreneurs. Xynomic Pharma focuses on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck, and Roche) in R&D roles. The founders also had successful entrepreneurial experiences including founding, building, and exiting successful US-China biopharmaceutical companies. Xynomic Pharma aims to build a comprehensive clinical and pre-clinical stage oncology pipeline targeting cancers with high prevalence in China, US and rest of the world. Xynomic Pharma leverages global resources, enabling the company to develop drugs in a cost and time-efficient manner. Xynomic Pharma is headquartered in the Shanghai with major operations in US and Shanghai, China.

keywords:N/A

N/A

Total Funding

15

Number of Employees

$3M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.3M157%N/A
#2
$1.3M15N/AN/A
#3
$1.4M1633%N/A
#4
$1.5M170%N/A
#5
$1.5M17-15%N/A